Trusted Resources: Community Center
A Guide to Understanding MPS I
MPS I is a mucopolysaccharide disease also called Hurler, Hurler-Scheie and Scheie syndrome. Hurler takes its name from Gertrude Hurler, the doctor who described a boy and girl with the condition in 1919. In 1962, Dr. Scheie, a consultant ophthalmologist, wrote about patients who were more mildly affected. Individuals who do not fit the severe or mild ends of the disease were said to have Hurler/Scheie.
The specific disease names have been replaced with the designations attenuated (diminished severity) and severe MPS I. MPS I has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS I.
BookmarkRelated Content
-
A 1-Year and 4-Month-Old Child With Mucopolysaccharidoses Type II: A Clinical Case Report From EthiopiaMucopolysaccharidoses (MPSs) are a class...
-
Wendy FergusonWendy Ferguson is the President and Secr...
-
Mucopolysaccharidosis Market: Global Industry Analysis and Opportunity Assessment 2022-2029The wide ranging Mucopolysaccharidosis M...
-
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, ...The "Mucopolysaccharidosis I (MPS I) (Hu...
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
Real World Long-Term Outcomes in Patients With Mucopolysaccharidosis Type II: A Retrospective Cohort StudyWe investigated the decline of activitie...
-
Elizabeth F. Neufeld, PhDBorn in France, Elizabeth Neufeld immigr...
